Biosimilars Oncology Roundup for June 2024—Podcast Edition
Season 6 Episode 33 · Jul 07, 2024, 11:00 AM
Share
Subscribe
On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Show notes
1. Biosimilars Check-In: Application Acceptances, European Approvals, New Partnerships
2. Overcoming Economic, Noneconomic Barriers to Biosimilar Adoption in Oncology
3. EHA 2024: Rituximab Biosimilars Improve Quality of Life, Infusion-Related Reactions
4. New Data Show Safety of Ado-Trastuzumab, Trastuzumab Biosimilars in HER2+ Cancers
5. ASCO Posters Reflect on Reimbursement Trends, Combination Therapies Involving Biosimilars
6. ASCO 2024 Posters Showcase Positive Data on Denosumab, Pegfilgrastim Biosimilars
7. Authors Spotlight Long-Term Solutions to Ensure Biosimilar Market Sustainability
8. Part 2: Unlocking the Potential of Biosimilars to Improve Health Equity
2. Overcoming Economic, Noneconomic Barriers to Biosimilar Adoption in Oncology
3. EHA 2024: Rituximab Biosimilars Improve Quality of Life, Infusion-Related Reactions
4. New Data Show Safety of Ado-Trastuzumab, Trastuzumab Biosimilars in HER2+ Cancers
5. ASCO Posters Reflect on Reimbursement Trends, Combination Therapies Involving Biosimilars
6. ASCO 2024 Posters Showcase Positive Data on Denosumab, Pegfilgrastim Biosimilars
7. Authors Spotlight Long-Term Solutions to Ensure Biosimilar Market Sustainability
8. Part 2: Unlocking the Potential of Biosimilars to Improve Health Equity